As of June 2021, Semaglutide GLP-1 injections have been FDA-approved for weight loss rather than only the treatment of type 2 diabetes, but only for patients that qualify for the injections through a medical weight-loss program provided by a health care provider
PubMed Comparison decision path Use this comparison to narrow the provider review question Direct answer Best GLP-1 Without Insurance: 2026 Guide should help you decide which option deserves a clinical review, not force a one-size answer
The survey included 1,159 global healthcare professionals whose specialties ranged from primary care providers, physician assistants, nurse practitioners, cardiologists, endocrinologists, OBGYNs, and pediatric medicine
For individuals taking glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity), or the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound), maintaining adequate magnesium status may be particularly important
GCGRA, glucagon receptor agonist
However, healthcare professionals may prescribe them off-label for weight loss
